EUVIMEDEUVIMED entdecken
Crossref

Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis

Dae-Ho Choi, Hye-Lim Jang, Sung Hee Lim, Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Deok Geun Kim, Kyoung-Mee Kim, Jeeyun Lee

Pathology - Research and Practice · 2024

DOI: 10.1016/j.prp.2024.155473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Dae-Ho Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Proto-Oncogene Proteins p21(ras), Gene Amplification, Proto-Oncogene Mas. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Kirsten rat sarcoma virus (KRAS) is a prominent proto-oncogene. Several treatments for KRAS mutations have been developed. However, KRAS amplification, a KRAS alteration, is poorly understood, and there is currently no appropriate treatment other than conventional chemotherapy. This study aimed to elucidate the role of KRAS amplification in different types of cancers. METHODS: From October 2019 to June 2023, we performed next-generation sequencing using Trusight Oncology 500 on 3895 patients with 37 different cancer types at the Samsung Medical Center. We analyzed the distribution of KRAS amplification according to cancer type and its correlation with tumor mutation burden (TMB). Concomitant KRAS mutations were also identified. RESULTS: Of the total 3895 patients, 99 (2.5 %) had KRAS amplification. The highest frequency of KRAS amplification was detected in 2 % (27/1350) of patients with colorectal cancer, followed by 3.48 % (32/920) of patients with gastric cancer and 3.88 % (9/232) patients with of pancreatic cancer. MSI-High was not detected in patients with KRAS amplification. There was no correlation between KRAS copy number variation and TMB status. Among patients with KRAS amplification, 27.3 % (27/99) had a concomitant KRAS mutation. More than 50 % of patients had G12D or G12V mutations. In gastric cancer, patients with both KRAS amplification and mutation were extremely rare at 3.1 % (1/32); however, in colorectal cancer, more than half of the patients had KRAS amplification and mutation (51.9 %, 14/27). KRAS amplification and mutations are associated with mutations in tumor suppressor genes TP53, BRCA2, ARID1B, and PTCH1. CONCLUSIONS: Of the 3895 patients with metastatic solid tumors, 99 (2.5 %) had KRAS amplification, and next-generation sequencing analysis provided a deeper understanding of KRAS amplification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingProto-Oncogene Proteins p21(ras)Gene AmplificationProto-Oncogene MasMutationHumansFemaleMaleMiddle AgedAgedNeoplasmsAdultPrevalenceBiomarkers, TumorNeoplasm Metastasis

Stichwörter der Autor:innen

ChemotherapyKRASMetastasisNeoplasmsNext-Generation Sequencingand Tumor burden

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanProto-Oncogene MasMAS1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Health Sciences and Technology, Samsung Advanced Institute f…
  • Department of Clinical Genomic Center, Samsung Medical Center, Seoul 06351, South Korea; Department of Digital Health, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul 06351, S…
  • Department of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: jyunlee@skku.edu.

Zitieren

APA

Choi, D. H., Jang, H. L., Lim, S. H., Kim, S. T., Hong, J. Y., Park, S. H., Park, J. O., Kim, D. G., Kim, K. M., & Lee, J. (2024). Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155473

Vancouver

Choi DH, Jang HL, Lim SH, Kim ST, Hong JY, Park SH, et al. Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155473

BibTeX
@article{Choi2024,
  author = {Choi, Dae-Ho and Jang, Hye-Lim and Lim, Sung Hee and Kim, Seung Tae and Hong, Jung Yong and Park, Se Hoon and Park, Joon Oh and Kim, Deok Geun and Kim, Kyoung-Mee and Lee, Jeeyun},
  title = {Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis},
  journal = {Pathology - Research and Practice},
  year = {2024},
  doi = {10.1016/j.prp.2024.155473}
}
Kostenlos starten →